SOUTH SAN FRANCISCO,
California and
VANCOUVER, Canada, March 9, 2022 /CNW/ - ESSA Pharma Inc.
("ESSA" or the "Company") (NASDAQ: EPIX), a clinical
stage pharmaceutical company focused on developing novel therapies
for the treatment of prostate cancer, is pleased to announce the
results of the votes on matters considered at its Annual General
Meeting of Shareholders held virtually on March 9, 2022 (the "Meeting").
At the Meeting, the shareholders of the Company (the
"Shareholders") resolved to set the number of directors of
the Company at eight and re-elected to the board of directors, by
ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M.
Berger, Scott Requadt,
Marella Thorell, Alex Martin, and Sandy
Zweifach to serve in office until the next annual meeting or
until their successors are duly elected or appointed. Detailed
results of the voting in respect of the election of directors are
as follows:
Nominee
|
Votes
For
|
% Votes
For
|
Votes
Withheld
|
% Votes
Withheld
|
David R.
Parkinson
|
29,377,984
|
99.90%
|
28,772
|
0.10%
|
Richard M.
Glickman
|
29,253,929
|
99.48%
|
152,827
|
0.52%
|
Gary
Sollis
|
28,596,127
|
97.24%
|
810,629
|
2.76%
|
Franklin M.
Berger
|
20,684,413
|
70.34%
|
8,722,343
|
29.66%
|
Scott
Requadt
|
29,369,580
|
99.87%
|
37,176
|
0.13%
|
Marella
Thorell
|
28,847,371
|
98.10%
|
559,385
|
1.90%
|
Alex
Martin
|
26,914,856
|
91.53%
|
2,491,900
|
8.47%
|
Sandy
Zweifach
|
29,387,996
|
99.94%
|
18,760
|
0.06%
|
At the Meeting, the Shareholders also approved: (i) the
re-appointment of Davidson & Company LLP, Chartered
Professional Accountants, as auditors of the Company; (ii) an
amendment to the Company's omnibus incentive plan (as amended, the
"Amended Omnibus Plan") to increase the number of common
shares of the Company reserved and available for issuance under the
Amended Omnibus Plan; (iii) on a non-binding advisory basis, the
compensation of the Company's named executive officers; and (iv) on
a non-binding advisory basis, "one year" as the frequency of
solicitation for advisory shareholder approval of executive
compensation.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on
developing novel and proprietary therapies for the treatment of
patients with prostate cancer. For more information, please visit
www.essapharma.com and follow us on Twitter under @ESSAPharma.
View original
content:https://www.prnewswire.com/news-releases/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-301499745.html
SOURCE ESSA Pharma Inc